PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25201453-1	2014	Previous studies demonstrated that the CXCL12 peptide analogue CTCE-0214 (CTCE) has beneficial effects in experimental sepsis induced by cecal ligation and puncture (CLP).	ctce	63-67	chemokine (C-X-C motif) ligand 12	Mus musculus	39-45
27031787-4	2016	We examined the hypothesis that CTCE improves EC function in lipopolysaccharide (LPS)-induced ARDS through increasing miR-126 expression.	ctce	32-36	microRNA 126	Homo sapiens	118-125
27031787-8	2016	Thrombin-induced vascular leak was abrogated by both CTCE and SDF-1alpha.	ctce	53-57	coagulation factor II, thrombin	Homo sapiens	0-8
27031787-9	2016	CTCE also prevented thrombin-induced decreases of vascular endothelial (VE)-cadherin cell surface expression and expansion of the intercellular space.	ctce	0-4	coagulation factor II, thrombin	Homo sapiens	20-28
27031787-9	2016	CTCE also prevented thrombin-induced decreases of vascular endothelial (VE)-cadherin cell surface expression and expansion of the intercellular space.	ctce	0-4	cadherin 5	Homo sapiens	50-84
27031787-10	2016	CTCE increased miR-126 levels and induced activation of AKT/Rac 1 signaling.	ctce	0-4	microRNA 126	Homo sapiens	15-22
27031787-10	2016	CTCE increased miR-126 levels and induced activation of AKT/Rac 1 signaling.	ctce	0-4	AKT serine/threonine kinase 1	Homo sapiens	56-59
27031787-10	2016	CTCE increased miR-126 levels and induced activation of AKT/Rac 1 signaling.	ctce	0-4	Rac family small GTPase 1	Homo sapiens	60-65
27031787-11	2016	Cotreatment with a miR-126 inhibitor blocked the protective effects of CTCE on AKT activation and endothelial permeability.	ctce	71-75	microRNA 126	Homo sapiens	19-26
27031787-11	2016	Cotreatment with a miR-126 inhibitor blocked the protective effects of CTCE on AKT activation and endothelial permeability.	ctce	71-75	AKT serine/threonine kinase 1	Homo sapiens	79-82
27031787-13	2016	Intravenous injection of CTCE diminished the injury severity as evidenced by significant reductions in protein, immune cells, inflammatory cytokines and chemokines in the bronchoalveolar lavage fluid, increased miR-126 expression and decreased pulmonary vascular leak and alveolar edema.	ctce	25-29	microRNA 126	Homo sapiens	211-218
27031787-14	2016	Taken together, our data show that CTCE improves endothelial barrier integrity through increased expression of miR-126 and activation of Rac 1 signaling and represents an important potential therapeutic strategy in ARDS.	ctce	35-39	microRNA 126	Homo sapiens	111-118
27031787-14	2016	Taken together, our data show that CTCE improves endothelial barrier integrity through increased expression of miR-126 and activation of Rac 1 signaling and represents an important potential therapeutic strategy in ARDS.	ctce	35-39	Rac family small GTPase 1	Homo sapiens	137-142
26375818-3	2015	METHODS: The plasma stable CXCL12 analog CTCE-0214D was synthesized and administered subcutaneously shortly before LPS treatment.	ctce	41-45	chemokine (C-X-C motif) ligand 12	Mus musculus	27-33
26375818-9	2015	Furthermore, in all three organs investigated, CTCE-0214D diminished the LPS induced expression of CXCR4, CXCL12, TLR4, NF-kappaB, cleaved caspase-3 and gp91 phox, whereas heme oxygenase 1 expression and activity was induced above average.	ctce	47-51	chemokine (C-X-C motif) receptor 4	Mus musculus	99-104
26375818-9	2015	Furthermore, in all three organs investigated, CTCE-0214D diminished the LPS induced expression of CXCR4, CXCL12, TLR4, NF-kappaB, cleaved caspase-3 and gp91 phox, whereas heme oxygenase 1 expression and activity was induced above average.	ctce	47-51	chemokine (C-X-C motif) ligand 12	Mus musculus	106-112
26375818-9	2015	Furthermore, in all three organs investigated, CTCE-0214D diminished the LPS induced expression of CXCR4, CXCL12, TLR4, NF-kappaB, cleaved caspase-3 and gp91 phox, whereas heme oxygenase 1 expression and activity was induced above average.	ctce	47-51	toll-like receptor 4	Mus musculus	114-118
26375818-9	2015	Furthermore, in all three organs investigated, CTCE-0214D diminished the LPS induced expression of CXCR4, CXCL12, TLR4, NF-kappaB, cleaved caspase-3 and gp91 phox, whereas heme oxygenase 1 expression and activity was induced above average.	ctce	47-51	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	120-129
26375818-9	2015	Furthermore, in all three organs investigated, CTCE-0214D diminished the LPS induced expression of CXCR4, CXCL12, TLR4, NF-kappaB, cleaved caspase-3 and gp91 phox, whereas heme oxygenase 1 expression and activity was induced above average.	ctce	47-51	paired Ig-like receptor B	Mus musculus	153-157
26375818-9	2015	Furthermore, in all three organs investigated, CTCE-0214D diminished the LPS induced expression of CXCR4, CXCL12, TLR4, NF-kappaB, cleaved caspase-3 and gp91 phox, whereas heme oxygenase 1 expression and activity was induced above average.	ctce	47-51	heme oxygenase 1	Mus musculus	172-188
19588526-3	2009	RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors.	ctce	19-23	proprotein convertase subtilisin/kexin type 1	Homo sapiens	65-69
19588526-3	2009	RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors.	ctce	19-23	BCL2 apoptosis regulator	Homo sapiens	70-75
19588526-3	2009	RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors.	ctce	19-23	proprotein convertase subtilisin/kexin type 1	Homo sapiens	80-84
19588526-3	2009	RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors.	ctce	19-23	BCL2 apoptosis regulator	Homo sapiens	350-355
21274742-4	2012	Our findings demonstrate that CTCE-0214 in vivo significantly suppressed plasma tumor necrosis factor alpha (TNF-alpha) increases in acute endotoxemia and following zymosan-induced multiple organ dysfunction syndrome (MODS).	ctce	30-34	tumor necrosis factor	Mus musculus	80-107
21274742-4	2012	Our findings demonstrate that CTCE-0214 in vivo significantly suppressed plasma tumor necrosis factor alpha (TNF-alpha) increases in acute endotoxemia and following zymosan-induced multiple organ dysfunction syndrome (MODS).	ctce	30-34	tumor necrosis factor	Mus musculus	109-118
20830712-6	2011	Expression levels of VEGF were also found to be reduced by 42% with CTCE-9908 (p = 0.01).	ctce	68-72	vascular endothelial growth factor A	Mus musculus	21-25
17541466-6	2007	Surface antigen detection of CXCR4 was reduced upon treatment with SDF-1alpha or AMD3100 and it was enhanced by CTCE-9908.	ctce	112-116	C-X-C motif chemokine receptor 4	Homo sapiens	29-34
16123381-3	2006	Our results demonstrated that CTCE-0214 synergized with thrombopoietin (TPO), stem cell factor (SCF), or flt-3 ligand (FL) on the survival of stem and progenitor cells in culture.	ctce	30-34	thrombopoietin	Mus musculus	72-75
16123381-3	2006	Our results demonstrated that CTCE-0214 synergized with thrombopoietin (TPO), stem cell factor (SCF), or flt-3 ligand (FL) on the survival of stem and progenitor cells in culture.	ctce	30-34	kit ligand	Mus musculus	78-94
16123381-3	2006	Our results demonstrated that CTCE-0214 synergized with thrombopoietin (TPO), stem cell factor (SCF), or flt-3 ligand (FL) on the survival of stem and progenitor cells in culture.	ctce	30-34	kit ligand	Mus musculus	96-99
16123381-3	2006	Our results demonstrated that CTCE-0214 synergized with thrombopoietin (TPO), stem cell factor (SCF), or flt-3 ligand (FL) on the survival of stem and progenitor cells in culture.	ctce	30-34	FMS-like tyrosine kinase 3 ligand	Mus musculus	105-117
16123381-3	2006	Our results demonstrated that CTCE-0214 synergized with thrombopoietin (TPO), stem cell factor (SCF), or flt-3 ligand (FL) on the survival of stem and progenitor cells in culture.	ctce	30-34	FMS-like tyrosine kinase 3 ligand	Mus musculus	119-121